{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T16:40:49Z","timestamp":1758127249039},"reference-count":23,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Department of Pharmaceutical Biochemistry and the Faculty of Pharmacy, Poznan University of Medical Sciences in Pozna\u0144, Poland"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology - Research and Practice"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.prp.2017.12.010","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T23:04:56Z","timestamp":1513292696000},"page":"314-317","update-policy":"http:\/\/dx.doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Frequent methylation of DAB2, a Wnt pathway antagonist, in oral and oropharyngeal squamous cell carcinomas"],"prefix":"10.1016","volume":"214","author":[{"given":"Jaroslaw","family":"Paluszczak","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Kiwerska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Mielcarek-Kuchta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.prp.2017.12.010_bib0005","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3126\/nje.v6i4.17255","article-title":"Changing Trends in oral cancer \u2212 a global scenario","volume":"6","author":"Gupta","year":"2016","journal-title":"Nepal J. Epidemiol."},{"key":"10.1016\/j.prp.2017.12.010_bib0010","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1159\/000446117","article-title":"Global Epidemiology of Head and Neck Cancers: A Continuing Challenge","volume":"91","author":"Gupta","year":"2016","journal-title":"Oncology"},{"key":"10.1016\/j.prp.2017.12.010_bib0015","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1172\/JCI59889","article-title":"The molecular pathogenesis of head and neck squamous cell carcinoma","volume":"122","author":"Rothenberg","year":"2012","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2017.12.010_bib0020","doi-asserted-by":"crossref","DOI":"10.1186\/s40463-017-0185-3","article-title":"Epigenetics of oropharyngeal squamous cell carcinoma: opportunities for novel chemotherapeutic targets","volume":"46","author":"Lindsay","year":"2017","journal-title":"J. Otolaryngol. Head Neck Surg."},{"key":"10.1016\/j.prp.2017.12.010_bib0025","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.oraloncology.2010.11.006","article-title":"Frequent hypermethylation of DAPK, RARbeta MGMT, RASSF1A and FHIT in laryngeal squamous cell carcinomas and adjacent normal mucosa","volume":"47","author":"Paluszczak","year":"2011","journal-title":"Oral Oncol."},{"key":"10.1016\/j.prp.2017.12.010_bib0030","first-page":"1035","article-title":"WNT pathway in oral cancer: epigenetic inactivation of WNT-inhibitors","volume":"24","author":"Pannone","year":"2010","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.prp.2017.12.010_bib0035","first-page":"1253","article-title":"Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma","volume":"32","author":"Sogabe","year":"2008","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2017.12.010_bib0040","doi-asserted-by":"crossref","first-page":"2855","DOI":"10.1007\/s13277-014-2913-x","article-title":"The negative regulators of Wnt pathway-DACH1, DKK1, and WIF1 are methylated in oral and oropharyngeal cancer and WIF1 methylation predicts shorter survival","volume":"36","author":"Paluszczak","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.prp.2017.12.010_bib0045","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1007\/s00784-016-1946-5","article-title":"Prognostic significance of the methylation of Wnt pathway antagonists-CXXC4, DACT2, and the inhibitors of sonic hedgehog signaling-ZIC1 ZIC4, and HHIP in head and neck squamous cell carcinomas","volume":"21","author":"Paluszczak","year":"2017","journal-title":"Clin. Oral Investig."},{"key":"10.1016\/j.prp.2017.12.010_bib0050","first-page":"432","article-title":"Frequent loss expression of dab2 and promotor hypermethylation in human cancers: a meta-analysis and systematic review","volume":"30","author":"Zhang","year":"2014","journal-title":"Pakistan J. Med. Sci."},{"issue":"Suppl. 1","key":"10.1016\/j.prp.2017.12.010_bib0055","first-page":"S45","article-title":"Disabled-2: a modular scaffold protein with multifaceted functions in signaling, BioEssays: news and reviews in molecular","volume":"38","author":"Finkielstein","year":"2016","journal-title":"Cell. Dev. Biol."},{"key":"10.1016\/j.prp.2017.12.010_bib0060","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.1172\/JCI36125","article-title":"Epigenetic downregulation of human disabled homolog 2 switches TGF-beta from a tumor suppressor to a tumor promoter","volume":"120","author":"Hannigan","year":"2010","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.prp.2017.12.010_bib0065","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1111\/jop.12178","article-title":"Frequent hypermethylation of WNT pathway genes in laryngeal squamous cell carcinomas","volume":"43","author":"Paluszczak","year":"2014","journal-title":"J. Oral Pathol. Med."},{"key":"10.1016\/j.prp.2017.12.010_bib0070","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1038\/sj.onc.1210829","article-title":"The inhibitory effects of Disabled-2 (Dab2) on Wnt signaling are mediated through Axin","volume":"27","author":"Jiang","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2017.12.010_bib0075","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1038\/onc.2009.157","article-title":"Dab2 stabilizes Axin and attenuates Wnt\/beta-catenin signaling by preventing protein phosphatase 1 (PP1)-Axin interactions","volume":"28","author":"Jiang","year":"2009","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2017.12.010_bib0080","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.3748\/wjg.v12.i37.6041","article-title":"Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis","volume":"12","author":"Anupam","year":"2006","journal-title":"World J. Gastroenterol.: WJG"},{"key":"10.1016\/j.prp.2017.12.010_bib0085","doi-asserted-by":"crossref","first-page":"71169","DOI":"10.18632\/oncotarget.8460","article-title":"Low disabled-2 expression promotes tumor progression and determines poor survival and high recurrence of esophageal squamous cell carcinoma","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.prp.2017.12.010_bib0090","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.3892\/ijo.2013.2084","article-title":"Aberrant hypermethylation and reduced expression of disabled-2 promote the development of lung cancers","volume":"43","author":"Xie","year":"2013","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.prp.2017.12.010_bib0095","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/MAJ.0000000000000436","article-title":"Aberrant hypermethylation at sites \u221286 to 226 of DAB2 gene in non-Small cell lung cancer","volume":"349","author":"Li","year":"2015","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.prp.2017.12.010_bib0100","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/1471-2407-10-253","article-title":"Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma","volume":"10","author":"Tong","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.prp.2017.12.010_bib0105","doi-asserted-by":"crossref","first-page":"4307","DOI":"10.1038\/onc.2013.381","article-title":"miR-93-directed downregulation of DAB2 defines a novel oncogenic pathway in lung cancer","volume":"33","author":"Du","year":"2014","journal-title":"Oncogene"},{"key":"10.1016\/j.prp.2017.12.010_bib0110","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.canlet.2015.04.006","article-title":"MicroRNA-93 promotes cell growth and invasion in nasopharyngeal carcinoma by targeting disabled homolog-2","volume":"363","author":"Xu","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.prp.2017.12.010_bib0115","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1007\/s13277-015-3038-6","article-title":"Increased expression of miR-93 is associated with poor prognosis in head and neck squamous cell carcinoma","volume":"36","author":"Li","year":"2015","journal-title":"Tumour Biol."}],"container-title":["Pathology - Research and Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033817309342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0344033817309342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T21:19:20Z","timestamp":1656451160000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0344033817309342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0344033817309342"],"URL":"https:\/\/doi.org\/10.1016\/j.prp.2017.12.010","relation":{},"ISSN":["0344-0338"],"issn-type":[{"value":"0344-0338","type":"print"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Frequent methylation of DAB2, a Wnt pathway antagonist, in oral and oropharyngeal squamous cell carcinomas","name":"articletitle","label":"Article Title"},{"value":"Pathology - Research and Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.prp.2017.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier GmbH. All rights reserved.","name":"copyright","label":"Copyright"}]}}